Fresenius Kabi is expanding its growing biopharma portfolio through a new licensing agreement with Polpharma Biologics S.A. Fresenius Kabi will commercialize Polpharma Biologics’ vedolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback